A federal appeals court has allowed RICO claims to go forward against GlaxoSmithKline on allegations the company affected prices by misrepresenting the heart-related risks of taking Avandia.
A three-judge panel of the U.S. Court of Appeals for the Third Circuit on Monday upheld a district court’s decision denying the pharmaceutical giant’s efforts to toss the plaintiffs’ claims for unjust enrichment and violations of the Pennsylvania Unfair Trade Practices and Consumer Protection Law.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
